DABUR Dabur India Q4 FY26 results (Jan–Mar 2026) and concall
Dabur India reported a strong Q4 FY26 with consolidated revenue up 7.3% and domestic FMCG growing 9.5% driven by 6% volume growth. HPC and Health Care segments showed robust performance, with significant market share gains in key categories. However, geopolitical issues in the Middle East led to muted international growth and rising input costs, prompting price increases. Management expects sequential recovery and continued double-digit growth in key segments.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 8.5%, net profit up 17.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,144 | 2,448 | 1,965 | 2,470 | 2,235 +4% | 2,547 +4% | 2,132 +8% |
| EBITDA | 403 | 523 | 284 | 485 | 424 +5% | 555 +6% | 317 +12% |
| Net profit | 329 | 418 | 251 | 407 | 349 +6% | 439 +5% | 296 +18% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.





